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Glanzmann Thrombasthenia
Cooperation between Sequence Variants in Cis during Splice Site Selection
Ying Jin, Harry C. Dietz,* Robert A. Montgomery,‡ William R. Bell, Iain McIntosh, Barry Coller,§ and Paul F. Bray
Departments of Medicine, *Pediatrics, and ‡Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; and the
§
Department of Medicine, Mt. Sinai Hospital, New York 10029

Abstract
Glanzmann thrombasthenia (GT), an autosomal recessive
bleeding disorder, results from abnormalities in the platelet
fibrinogen receptor, GPIIb-IIIa (integrin aIIbb3). A patient
with GT was identified as homozygous for a G→A mutation 6 bp upstream of the GPIIIa exon 9 splice donor site.
Patient platelet GPIIIa transcripts lacked exon 9 despite
normal DNA sequence in all of the cis-acting sequences
known to regulate splice site selection. In vitro analysis of
transcripts generated from mini-gene constructs demonstrated that exon skipping occurred only when the G→A
mutation was cis to a polymorphism 116 bp upstream, providing precedence that two sequence variations in the same
exon which do not alter consensus splice sites and do not
generate missense or nonsense mutations, can affect splice
site selection. The mutant transcript resulted from utilization of a cryptic splice acceptor site and returned the open
reading frame. These data support the hypothesis that premRNA secondary structure and allelic sequence variants
can influence splicing and provide new insight into the regulated control of RNA processing. In addition, haplotype
analysis suggested that the patient has two identical copies
of chromosome 17. Markers studied on three other chromosomes suggested this finding was not due to consanguinity.
The restricted phenotype in this patient may provide information regarding the expression of potentially imprinted
genes on chromosome 17. (J. Clin. Invest. 1996. 98:1745–
1754.) Key words: RNA splicing • exon skipping • platelet
membrane glycoprotein complex IIb-IIIa • molecular genetics • Glanzmann thrombasthenia

Introduction
Glanzmann thrombasthenia (GT)1 is an autosomal recessive
bleeding disorder due to quantitative or qualitative abnormalities in the platelet fibrinogen receptor (1, 2). The disease was
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first described in 1918 by Glanzmann, a Swiss pediatrician (3).
In 1974 Nurden and Caen demonstrated the absence of platelet membrane glycoproteins IIb-IIIa (GPIIb-IIIa) in three patients with this disorder (4). Subsequent studies characterized,
isolated, and demonstrated that GPIIb-IIIa functioned as the
fibrinogen receptor in platelets (5–12), thus providing the biochemical explanation for the bleeding phenotype seen in GT.
With the isolation of cDNA and genomic clones for GPIIb and
GPIIIa (13–19), a number of mutations in the genes have been
identified which result in GT. The first molecular defect in
thrombasthenia was described in 1990 (20) and since then . 20
different mutations have been characterized (for review see
reference 21). These studies have provided a wealth of information about platelet physiology, as well as biochemical, immunologic, and molecular biologic information about GPIIbIIIa and other molecules which comprise the integrin family of
adhesive molecules (22, 23).
GT is categorized into three types according to the amount
of immunologically detectable GPIIb-IIIa: type I, , 5%; type
II, 10–20%; and variant thrombasthenia with nearly normal
levels of GPIIb-IIIa (1). Four mutant GPIIIa alleles have been
described in five kindreds with variant thrombasthenia (24–
28): three of these mutations affect two amino acids (Asp119
and Arg214) and demonstrate a necessary region for fibrinogen binding (24–26, 28). A third mutation alters the cytoplasmic Ser752 and impairs the signaling required for GPIIb-IIIa
function (27, 29). However, the patients with variant thrombasthenia represent only 8% of all thrombasthenics (1), and
the majority of mutations described to date have been in type I
patients. Most of these are caused by small mutations (30–40).
Of the 10 point mutations published in full form, five have resulted in mRNA splicing abnormalities (30–33, 38). These
splicing abnormalities usually generate unstable mRNAs
yielding no translated protein products, or in a few cases, truncated and dysfunctional protein products. Several point mutations have resulted in mRNA splicing defects in which entire
exons have been deleted (30, 31, 33). Although alternate exon
splicing has been thoroughly investigated (see reviews 41, 42),
many mechanistic details are still poorly understood. Most mutations which affect splicing are located within consensus splice
donor, acceptor, and branch sites and cause exon skipping as
opposed to cryptic splice site utilization (43, 44). Nakai et al.
scanned 209 mammalian genetic disease splicing mutations
and observed that . 90% create or destroy consensus sequences and that most occurred at the 59 splice site region;
none were upstream of the 21 position (45).
We previously reported the preliminary characterization of
a patient with type I GT who had an unusual mutation resulting in abnormal mRNA splicing manifested by the skipping of
exon 9 in the GPIIIa gene (46). We now report the full characterization of this genetic defect and the inheritance of the mutant allele. Our data indicate that a mutation 6 bp upstream of
the splice donor site of exon 9 acts in concert with an addi-
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tional exonic sequence variation to cause exon skipping with
the subsequent utilization of a cryptic splice site, and that the
phenotype in this patient was apparently due to disomy of
chromosome 17. We discuss the possible reasons for these
splicing abnormalities and the genetic implications of chromosome 17 disomy.

Methods
Subjects. Subject RS is a 24-yr-old African American female with a
lifelong bleeding history. Her bleeding is primarily from her nasal and
gingival mucosa and with her menses. She required platelet transfusions at age 10 for epistaxis. Her clinical features are typical for Glanzmann thrombasthenia and careful history and physical examination
revealed no unusual or additional clinical findings. Her platelets do
not aggregate in response to physiologic stimuli, but do aggregate to
ristocetin. Platelets from the patient had trace amounts of GPIIb, but
lacked detectable GPIIIa by Western immunoblotting and have been
previously shown not to bind soluble fibrinogen (47). No history of
consanguinity could be elicited despite intense questioning. The father is unavailable for study. The mother of the patient was asymptomatic and had normal platelet aggregation. Blood from normal individuals was used to prepare genomic DNA for control experiments.
All of these studies have been conducted according to the principles
expressed in the Declaration of Helsinki.
Reagents. Taq polymerase was from Perkin Elmer Cetus Corp.
(Norwalk, CT), isotopes were from Amersham Corp. (Arlington
Heights, IL), ds Cycle Sequencing System from Gibco BRL (Gaithersburg, MD).
Quantitation of vitronectin receptors. Monoclonal antibody LM609
(the generous gift of Dr. David Cheresh, Scripps Research Institute,
La Jolla, CA) specific for avb3 was used to quantitate the platelet vitronectin receptor as previously described (48).
Single strand conformation polymorphism (SSCP) analysis. Preparation of genomic DNA and screening for mutations was performed by SSCP analysis as previously described (31). Radiolabeled
PCR products were denatured in 95% formamide and electrophoresed through 6% acrylamide, 10% glycerol, and 1 3 TBE (89 mM
Tris-borate pH 5 8.3, 2 mM EDTA) nondenaturing gels. The gels
were run for 16 h at 10 W at room temperature, dried, and exposed to
film for 48 h.
Oligonucleotide synthesis. Oligonucleotides for SSCP were as
previously described (31). Primers for RNA analysis were designed
from GPIIIa cDNA sequence (16) and are listed in Table I. Nucleotide sequence numbering is according to Zimrin et al., (18); exon
numbering, according to Villa-Garcia et al., (19) and Zimrin et al.
(18).

RNA preparation. Total platelet RNA was prepared and reverse
transcribed into cDNA with random primers as previously described
(49). Using oligonucleotides designed from exonic sequence, the
platelet cDNA was amplified and analyzed on 2% agarose gels. Abnormal fragments were gel purified and the nucleotide sequence determined as described below.
Nucleotide sequence determination. Sequence information was
obtained from eluted DNA from SSCP gels (31), directly from amplified genomic DNA, or from reverse transcribed platelet mRNA. 2 ml
of the PCR products were used in a sequencing reaction which included a [g-33]P-labeled primer and 2.5 units Taq polymerase (ds Cycle Sequencing System; Gibco BRL). 20–30 cycles of amplification
were performed as previously described (31). Extension products
were separated on 6% acrylamide/7 M urea gels and assayed by autoradiography.
Southern blot analysis. Genomic DNA preparation for Southern
blot analysis, as well as the blotting procedure were performed as previously described (20). A 2.0-kb cDNA probe 59 to the internal
EcoRI site in the GPIIIa cDNA (50) and a 345-bp probe containing
exons 1–3 of the fibrillin cDNA (51) were used for genomic DNA hybridizations. Equivalency of loading between lanes was determined
by using the ImageQuaNT version 4.1 software on a phosphorimager,
(445SI-486; Molecular Dynamics, Sunnyvale, CA).
Reverse transcriptional PCR (RT-PCR) products derived from
platelet RNA were separated on a 2% agarose gel, transferred to nylon filters, and hybridized with an internal oligonucleotide as described (52). Relative abundance of RNA transcripts was determined
by carefully aligning the autoradiogram with the filter, cutting out
that portion of the filter corresponding to a particular band, and determining the signal strength with a scintillation counter.
Minigene transcript analysis of mutant and wild-type alleles. Approximately 2 kb of genomic DNA was PCR amplified from the patient and her mother using PCR primers RSY.S and RSY.A contained in exons 8 and 10, respectively. These fragments were cloned
in frame into the ornithine d-aminotransferase (OAT) cDNA contained in pGEM-4Z (Promega Corp., Madison, WI) as described
(52). The EcoRI fragment from these plasmids were isolated and
cloned into the pcDNAI/Amp expression plasmid (Invitrogen, San
Diego, CA), and mapped for the proper orientation. The nucleotide
sequence of the entire exon 9 and the flanking 50 bp was determined,
and demonstrated that we had isolated the wild-type maternal allele
(pcDNA.E1), the mutant maternal allele (pcDNA.E2), and the single
patient allele (pcDNA.RS).
Point mutations were introduced into pcDNA.E1 and pcDNA.RS
using the Altered Sites II in vitro mutagenesis kit (Promega Corp.).
Briefly, the EcoRI fragments of pcDNA.E1 and pcDNA.RS were
cloned into pALTER-1 and single-strand DNA prepared. The desired mutation was generated using a synthetic oligonucleotide and

Table I. GPIIIa Oligonucleotide Primers
Name

3H.S
3H.A
3a24
3IA1
RA1
RA3
3aex8
RSY.S
RSY.A

Sequence (59 to 39)

Location:description

cagttcaattcttgtcttcttgt
gctccaggacaaaggccct
TATCCCTCTTTGGGGCTGATGACTG
AAGGGCGATAGTCCTCCTC
ACCTTGGCCTCAATGCTGAAG
CAATGCTGAAGCTCACCCCATA
CCAGCTCATTGTTGATGCTT
ACCGGAACCAATTCTGTCCATGGATTCCAGCA
GGCATGCATCAAAGGTGACCTGGACGAT

intron 8 for SSCP of exon 9
intron 9 for SSCP of exon 9
exon 7 for mRNA analysis
exon 10 for mRNA analysis
exon 10 for mRNA analysis
spans exons 10 and 8
exon 8 probe for Southern
exon 8 sense for minigene
exon 10 antisense for minigene

Intron sequence in lowercase; exon 8 sequence underlined; artificial sequences for cloning purposes are in italics; XmnI and NsiI restriction sites are
in bold.
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T4 DNA polymerase, subcloned back into pcDNAI/Amp, and the
plasmid was sequenced to confirm the mutation had been properly
introduced.
Plasmid DNA was purified using Nucleic Acid purification columns (Qiagen Inc., Chatsworth, CA) and electroporated into K562
cells as described (19). 16 h later total RNA was isolated, reversed
transcribed into cDNA, and analyzed by PCR amplification with
OAT and GPIIIa specific primers. To confirm the identity of these
PCR products, they were cloned into the pCRII plasmid (Invitrogen)
and sequenced.
Microsatellite analysis. Oligonucleotides were used to PCR amplify the region of genomic DNA known to contain polymorphic dinucleotide repeats. These primers have been described previously
(53–55) and were identified by searching the official Genome Data
Base (GDB) (56, 57) source node at Johns Hopkins University in
Baltimore on the GDB main computer. PCR conditions were as
above except the sense primer was end-labeled with 32P-gATP and
the annealing temperatures varied between 55–628C. Products were
separated in 6% acrylamide/7-M urea gels, and assayed by autoradiography.
RNA secondary structure prediction. RNA secondary structure
was analyzed by the algorithm of Zuker and Stieger (58) using the
computer program RNAFOLD in the PC/GENE software from IntelliGenetics (Mountain View, CA) on a Computer Ergonomics (Columbia, MD) 486 computer. The input sequence contained all of exon
9 (four combinations of sequence variants) and the last and first 10 bp
of introns 8 and 9, respectively. A graphic display was generated from
this prediction using the program MOLECULE written by Dr. J.
Ryan Thompson (Carnegie-Mellon University, Pittsburgh, PA) according to the algorithm of Lapalme et al. (59).

Results
Because the molecular defect in GT may be in either of two
genes, we performed preliminary studies to assess GPIIIa expression. Platelets from patient RS and a normal control were
studied for their vitronectin receptor (avb35av/GPIIIa) content (48). The patient’s platelets did not bind an antibody to
the vitronectin receptor (LM609), suggesting a GPIIIa defect
(data not shown). Genomic Southern blotting of patient DNA
using a series of restriction enzymes was normal (see below),
suggesting normal gene dosage and the lack of a large rearrangement. We used the SSCP technique to analyze all GPIIIa
exons from patient RS. Fig. 1 A shows such an analysis of exon
9 from a group of normal individuals and patient RS. Despite
the presence of additional bands due to the known silent C/A
polymorphism at position 20507 in this exon (18), a clearly abnormal pattern of migration was seen for the sample from RS
(Fig. 1, lane 13). The abnormal 209-bp fragment was isolated
and sequenced, and a G to A substitution was found 6 bp upstream of the splice donor site (ACGGTGAGgt→ACAGTGAGgt) at position 20624 of the GPIIIa gene (Fig. 1 B). There
were no other nucleotide differences between the sequence
from the patient DNA fragment and that of the normal control. This G to A substitution represents a synonymous change
and has not previously been reported. To address whether this
sequence change represented a polymorphism, we performed
SSCP analysis of exon 9 on DNA samples from 45 normal individuals and 4 additional patients with GT (90 and 8 chromosomes, respectively). In no case did we find the SSCP pattern
corresponding to this G to A transition (data not shown). Because the patient was African American, we also studied DNA
from 58 African Americans using an HphI restriction digest of
the PCR fragments (the HphI recognition sequence is specifi-

Figure 1. SSCP analysis of exon 9 of the GPIIIa gene. (A) PCR
amplified genomic DNA from 11 different normal individuals (lanes
1–12) and patient RS (lane 13) using primers 3H.S and 3H.A. The
variable bands seen in the normal individuals have been previously
sequenced (31) and are due to the known silent polymorphism in this
exon (18). (B) Nucleotide sequence of exon 9 SSCP products. (Left)
sequence of a fragment derived from a normal individual; (right)
sequence of the fragment indicated by the arrow in Fig. 1 A.

cally encoded by the G variant) and again found no alleles
containing the A at position 20624. Thus, the A was not
present in 206 chromosomes from normal individuals lessening
the possibility that the sequence variation at position 20624
represents a polymorphism.
Direct sequencing of genomic DNA revealed the patient
was homozygous for the G to A substitution, suggesting this
may be responsible for the nonexpression of GPIIIa. However, because this nucleotide substitution does not change an
amino acid, we sought to determine whether it alters premRNA splicing. The major PCR product identified when patient platelet RNA was amplified with sense and antisense
primers complementary to regions of exons 7 and 10, respectively, was smaller than normal (Fig. 2 A, lane 3). There were
also two less abundant products of approximately normal size
observed in the patient sample which were only consistently
seen upon overloading of PCR products (see below). Isolation
and sequencing of the major 442-bp fragment from the patient
sample revealed the absence of exon 9 but the insertion of 5 bp
between the sequences corresponding to exons 8 and 10. (Fig.
2 B). These 5 bp match precisely the 5 bp preceding the exon
10 spice acceptor site and are preceded in genomic DNA by an
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Figure 2. Platelet GPIIIa RNA analysis. (A) The cartoon on the left
indicates the relative positions of the PCR primers in exons 7 and 10
of the GPIIIa gene, and does not reflect a specific sized PCR product.
To the right is shown an ethidium-stained agarose gel containing
products from RT-PCR reactions using primers 3a24 and 3IA1 with
no input template (lane 2), and platelet cDNA from a normal individual (lane 3), and patient RS (lane 4). Size markers are fx174 DNA digested with HaeIII (lane 1). (B) Nucleotide sequence of the fragments shown in A. (Left) GPIIIa mRNA from normal platelets;
(right) platelet GPIIIa mRNA from RS.

AG dinucleotide. This suggested that the majority of the transcripts manifest the skipping of exon 9 and the utilization of a
cryptic splice acceptor site 5 bp upstream of exon 10. Note that
the isolated skipping of exon 9 would result in a frameshift and
consequent premature termination codon, and mutant transcript instability would be predicted (52). However, some proportion of such transcripts utilize a cryptic splice site, restoring
the open reading frame (ORF) and hence stability of those
molecules. We have determined the sequence of the two faint

upper bands seen in Fig. 2 A, lane 4. The lower of these two is
normal in size, contains exon 9, the G to A substitution, and
otherwise has normal sequence (data not shown). The slightly
larger than normal fragment has been difficult to separate
from the normal fragment, but the sequence we have obtained
indicates it is a heteroduplex comprised of both the 577 and
442 bp cDNA species. Fig. 3 summarizes the abnormal splicing
from the mutant allele and indicates the position of the cryptic
splice site.
We considered several additional issues with respect to the
molecular genetics of this mutation. First, is the G to A substitution in exon 9 necessary to cause the abnormal splicing phenotype? Second, is the G to A substitution in exon 9 sufficient
to cause the abnormal splicing phenotype? Third, how was the
abnormal allele inherited? To address the first question we determined the nucleotide sequence corresponding to all of the
cis-acting elements known to influence splice site selection.
These include the splice donor, branch point, and splice acceptor for introns 8 and 9 (Fig. 3). No sequence alteration was
identified in these regions, and we conclude that the G to A
substitution in exon 9 is associated with, and perhaps necessary
for the abnormal splicing.
Since the mother is heterozygous for the G→A substitution
(see below), if the G→A substitution causes exon skipping we
would predict that some portion of her platelet GPIIIa transcripts would demonstrate exon 9 skipping. To determine
whether exon 9 skipping did not occur at low levels in normal
individuals and to study maternal transcripts, we analyzed
platelet RNA from the mother, the patient, and a series of normal individuals (Fig. 4 A). Using primers flanking exon 9, we
observed a faint band in the mother’s sample (Fig. 4 A, lane 2)
which comigrated with the fragment manifesting exon skipping from RS. The abnormal fragment was not seen in platelet
RNA from normal individuals (Fig. 4 A, lanes 1, 4–9). Although we did not rigorously attempt to perform a quantitative RT-PCR, these data nevertheless suggested that a small
percent of the maternal platelet mRNA contained GPIIIa
transcripts lacking exon 9. We confirmed this by utilizing an
antisense PCR primer which would only anneal to cDNA derived from mRNA that had skipped exon 9 and utilized the
cryptic splice site in intron 9 during splicing. Fig. 4 B demonstrates that platelet total RNA from the patient (Fig. 4 B, lane
3) and the mother (Fig. 4 B, lane 2), but not a normal control
Figure 3. Model for the splicing
abnormality in the major
GPIIIa transcript. The wild-type
G and mutant A at position
20624 are indicated with vertical
arrows. Note the cryptic splice
site and polypyrimidine tract
which immediately precede the
normal exon 10 splice acceptor
site. Several features of the mutant transcript are illustrated:
the skipping of exon 9 and the
additional 5 bp between exons 8
and 10. Regions for which nucleotide sequence was determined are indicated by horizontal arrows, with the numbers of
nucleotides sequenced indicated
below.
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Figure 4. Analysis of GPIIIa exon 9 splicing. (A) Primers 3a24 and
3IA1 were used to amplify cDNA from normal (lanes 1, 4–9), maternal (lane 2), and patient (lane 3) platelets. Size markers (M) are
fx174 DNA digested with HaeIII. Position of primers on each transcript is displayed to the right. The 5-bp insertion in the smaller transcript is not shown. (B) Primers 3a24 and RA3 were used to amplify
cDNA from normal (lane 1), maternal (lane 2), and patient (lane 3)
platelets. Primer RA3 is specific for mRNA lacking exon 9 that has
utilized the cryptic splice site. Different antisense primers RA3 and
RA1 were used for products shown on this gel, and are indicated below. Primers 3a24 and RA1 were used to amplify cDNA from normal
(lanes 4, 7–11), maternal (lane 5), and patient (lane 6) platelets.
Primer RA1 will amplify mRNA independent of the presence of exon
9. Size markers (M) are fx174 DNA digested with HaeIII. Note that
antisense primers RA1 and RA3 generate smaller products than seen
in A. (C) Southern analysis of PCR products indicating relative abundance of GPIIIa transcripts with or without exon 9. Normal (lanes 1
and 4), maternal (lane 2), and patient (lane 3) platelet RNA was reverse transcribed, PCR amplified with primers 3a24 and 3IA1, separated in 1.5% agarose, transferred to nylon membranes, and hybridized with 32P-labeled primer 3aex8. The same filter is shown twice,
with the length of exposure to film at 2808C indicated above each exposure. In refers to transcripts containing exon 9; out to transcripts
lacking exon 9.

(Fig. 4 B, lane 1), contain such transcripts. Shifting the antisense primer 10 bp in the 39 direction, such that it is entirely
complementary to exon 10 sequence, allows the amplification
of the “exon in” species in normal individuals (Fig. 4 B, lanes
4, 7–11) and both the “exon in” and “exon out” species in the

mother (Fig. 4 B, lane 5) and patient (Fig. 4 B, lane 6). We
used Southern blot analysis to estimate the relative abundance
of the two species of GPIIIa mRNA in the mother’s platelets
and to confirm the identity of the smaller cDNA fragment
(Fig. 4 C). Prolonged exposures revealed the exon out form in
the maternal amplified cDNA (Fig. 4 C, lane 6) but not in normal controls (Fig. 4 C, lanes 5 and 8). Within the limits of this
RT-PCR amplification, we estimate that the exon 9 deleted
form represents z 3% of the maternal platelet GPIIIa transcripts. These comprehensive RNA analyses indicated that (a)
the maternal and patient 442-bp amplified fragment (Fig. 2 A
and Fig. 4 A) was indeed the result of exon 9 skipping, and (b)
this abnormal splicing did not appear to occur in normal individuals. These data also suggest the G→A substitution was
necessary for exon 9 skipping.
To prove whether the G to A transition is necessary and
sufficient to dictate abnormal splicing, we analyzed the splicing
of this portion of the GPIIIa gene transfected into K562 cells.
Fig. 5 A schematically displays the minigene constructs used in
these experiments. As shown in Fig. 5 B, the patient’s allele
and the mother’s mutant allele cause exon 9 skipping (Fig. 5 B,
lanes 2 and 4), whereas the mother’s wild-type allele splices
normally (Fig. 5 B, lane 3). Note that in the context of these artificial minigene constructs this abnormal splicing process is
not maximally efficient and a substantial portion of the processed transcripts contain exon 9. The key finding, however, is
that exon 9 is deleted only in the presence of the G to A substitution (Fig. 5, lanes 2 and 4). To confirm the identity of the
PCR products in lanes 2 and 3 we subcloned and sequenced
these fragments (data not shown). The larger fragments in
lanes 2 and 3 contained sequence for OAT and GPIIIa exon
8–10. The smaller fragment in lane 2 contained OAT and
GPIIIa exon 8 and 10 sequence, with the previously identified
5 bp of intronic sequence between exons 8 and 10.
We next analyzed splicing of the patient and wild-type maternal alleles in which the 26 position from the splice donor
site of intron 9 had been switched; i.e., to a wild-type G in the
patient allele and a mutant A in the maternal allele. The mutation in patient exon 9 is necessary for exon skipping, since replacing it with the normal G corrects the splicing abnormality
(Fig. 5 B, lane 7). However, introducing the mutant A into the
maternal wild-type allele was not sufficient to cause exon skipping (Fig. 5 B, lane 5). Because the G to A substitution in exon
9 could not be solely responsible for the splicing defect, and
because the mother was heterozygous for the C/A polymorphism at the 59 end of exon 9 (nucleotide 20507), while the patient was homozygous A at this position, we hypothesized that
the G to A mutation at the 39 end of exon 9 (position 20624)
would result in abnormal splicing only when allelic with the 59
polymorphic A. This hypothesis is summarized in Fig. 5 C. To
exclude the possible contribution to splicing of any other sequence variations in the maternal mutant allele, we introduced
both sequence substitutions into the maternal wild-type allele.
We observed that the 39 A caused abnormal splicing only in
the context of the 59 A (compare Fig. 5 B, lane 6 with lane 5).
We were puzzled by the fact that the patient was homozygous for the G to A substitution, since this appeared to be an
exceedingly rare sequence variant and there was no history of
consanguinity. One possibility consistent with this finding was
haploinsufficiency due to a large gene deletion. The quantitative Southern blot data shown in Fig. 6 discount this explanation. Fig. 6 A indicates that equivalent amounts of normal, ma-
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Figure 5. In vitro analysis of transcripts generated from the mutant
allele. (A) 2 kb of contiguous GPIIIa gene from exons 8 to 10 from
the patient and her mother were engineered in frame into the OAT
cDNA in the pcDNAI expression plasmid. Plasmids were transfected
into K562 cells and the resulting transcripts analyzed 16 h later by
RT-PCR using primers E5S (59-GAGACTGCCTGTAAACTAGC39) and RA1, specific for OAT (60) and GPIIIa, respectively. In some
constructs, position 26 to the splice donor site was mutated to G or
A; similarly, position 118 from the splice acceptor site was mutated
from a C to an A. Note that exon 9 is 140 bp. (B) Templates for PCR
reactions were: no template cDNA (lane 1), cDNA from K562 cells
transfected with constructs containing the patient’s mutant allele
(lane 2, RS), the maternal wild-type allele (lane 3, E1), the maternal
mutant allele (lane 4, E2), the maternal wild-type allele in which the
G at position 20624 had been mutated to an A (lane 5, mE1), the maternal wild-type allele in which the C at position 20507 had been mutated to an A and the G at position 20624 had been mutated to an A
(lane 6, m2E1), and the patient’s mutant allele in which the A at position 20624 had been mutated to a G (lane 7, mRSY). PCR products
were amplified with E5S and RA1. Diagram to right of the gel demonstrates exon composition of transcripts. Size markers (M) are
fx174 DNA digested with HaeIII. In controls not shown, cDNA
from K562 cells that were not transfected with an OAT-GPIIIa minigene construct yielded no PCR products with primers E5S and RA1,
but did amplify with control GPIIIa sense and antisense primers demonstrating the template cDNA was able to be amplified. (C) Hypothesis for exon 9 skipping in patient RS. The nucleotide positions of the
59 polymorphism and the 39 mutation are indicated above. As referenced in the text, the C at position 20507 creates a TaqI site; the G at
20624, an HphI site.

ternal, and patient genomic DNA were loaded (Fig. 6 A, lanes
1–6). In Fig. 6 B, note the equivalent intensity of the z 3.3 and
z 5.2 kb TaqI fragments between the control (Fig. 6 B, lane 1)
and the patient (Fig. 6 B, lane 3), as well as all BamHI frag1750
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ments (Fig. 6 B, lanes 4–6), indicating that the patient has two
copies of the GPIIIa gene. Essentially equivalent DNA loading of all lanes was confirmed by reprobing this filter with a
cDNA probe from the fibrillin gene (Fig. 6 B, lanes 7–12).
Because the patient was homozygous for a total of three
GPIIIa polymorphisms, including the TaqI polymorphism at
position 20507 of exon 9 (as shown in Fig. 6 B), we considered
the possibility that she had two identical or nearly identical
copies of chromosome 17. To address this issue, we examined
five highly informative microsatellite polymorphisms distributed throughout chromosome 17. We found that the patient
was homozygous for all five of these markers (Fig. 7 A). Note
the normal control is heterozygous for D17S849, D17S250, and
D17S801 and homozygous for D17S799, and D17S784. The
mother is heterozygous for D17S799 and D17S784, and homozygous for D17S250, D17S801, and D17S849. Using the calculated population frequencies for the different marker alleles,
there is a 1 in 2,000 chance that an individual would be homozygous for all five markers. The frequency of the GPIIIa
polymorphisms are not known, but we have analyzed 40 unrelated individuals to determine the allelic frequencies at position 20507 (data not shown). The frequency of the homozygous “A” state is 0.39. By including this GPIIIa marker, there
would be only a 1 in 5,000 chance that an individual would be
homozygous for these 6 chromosome 17 polymorphisms,
strongly suggesting two copies of the same chromosome 17 in
this patient. This idea becomes virtually certain if one considers that none of the 206 normal chromosomes studied had the
A at position 20624.
Two identical copies of a chromosome may result when
both copies were inherited from one parent (uniparental isodisomy), or as a product of a consanguinous union. To address
these possibilities, we analyzed chromosomes 3, 4, and 7 to determine if the patient had the expected frequency of heterozygosity elsewhere in the genome. We studied two polymorphic
markers on each chromosome and found that similar to the
control, the patient was heterozygous for four of the six markers (Fig. 7 B). Because paternal DNA was not available for
study, we cannot eliminate the possibility of consanguinity
with 100% certainty. However, the studies on chromosomes 3,
4, and 7 are inconsistent with a consanguineous inheritance.

Discussion
We have performed a detailed molecular genetic analysis of
the GPIIIa gene in a patient with GT and identified a novel
mechanism for producing the thrombasthenic phenotype as
well as a novel cause of exon skipping. The most significant
findings from our studies are (a) that two sequence variations
within a single exonic which do not alter consensus splice sequences and which do not generate nonsense or missense mutations, can produce an RNA splicing abnormality. The profound effect on splicing of such nucleotide changes supports a
hypothesis whereby exon secondary structure effects mRNA
splicing; (b) we believe this to be the first example of chromosome 17 disomy in any human disease; (c) Assuming this patient inherited two copies of maternal chromosome 17, the
lack of any additional clinical phenotype beyond that of typical
GT has implications regarding the possibility of imprinted
genes on chromosome 17.
The spectrum of mutations identified to date in type I
thrombasthenia includes nonsense mutations, frameshift mu-

Figure 6. Southern blot demonstrating patient RS has two
GPIIIa genes. (A) Ethidium
stained 0.8% agarose gel containing 7.5 mg of genomic DNA
digested with TaqI (lanes 1–3)
or BamHI (lanes 4–6) from a
normal control (lanes 1 and 4),
the patient’s mother (lanes 2
and 5), and the patient (lanes 3
and 6). Size markers (M) are
lDNA digested with HindIII
and fx174 DNA digested with
HaeIII. (B) The gel in A was
transferred to a nylon membrane and hybridized with a 32Plabeled 2.0 kb GPIIIa cDNA
(lanes 1–6) or 345 bp fibrillin
cDNA probe (lanes 7–12). Note
the patient is homozygous for the uncommon form of the known TaqI polymorphism. This results in the absence of the z 4.6- and z 2.9-kb fragments, and the double intensity of the z 7.5-kb fragment. PhosphorImager analysis of the fibrillin hybridization indicated that relative to the
normal control (lanes 7 and 10), an essentially equivalent amount (68%) of RS genomic DNA was loaded (lanes 9 and 12).

tations, and mutations that interfere with pre-mRNA splicing.
The unifying factor appears to be a deficiency of functional
protein, either due to unstable transcripts or the production of
unstable or truncated and dysfunctional protein products. Iwamoto et al. described a patient with a nonsense mutation in
exon 28 of the GPIIb gene which resulted in exon 28 skipping
(33). One of the mutant alleles described by Kato et al. produced a GPIIb transcript lacking exon 26 secondary to a C→G
mutation at the 23 position of the exon 26 splice acceptor site
(30). And we have described exon 5 skipping in the GPIIIa
gene due to a G to A mutation at position 11 of the splice donor site (31).
The mutation described in this report results in the skipping of exon 9 of the GPIIIa gene. This mutation is unusual in
several respects. First, the G→A substitution is 6 bp upstream

of the exon 9 splice donor site, a position that shows no apparent sequence preference nor conservation in mammalian
genes (61). None of the 24 single base mutations affecting exon
splicing identified by Chen and Chasin were located in the 26
position from the splice donor site (44). To consider alternate
mutations as the cause for exon 9 skipping, we sequenced the
patient’s entire exon 9 and flanking regions known to affect
splice site selection, but the only abnormality was the G→A
substitution. Because none of 206 chromosomes from 103 normal individuals contained this nucleotide change, it does not
satisfy the definition of a polymorphism.
The G→A mutation was necessary but not sufficient to effect exon 9 skipping in our patient’s GPIIIa gene, and required
the presence of an additional distal allelic variation. The patient allele is polymorphic for a known substitution at the 59

Figure 7. Microsatellite analysis
of chromosome 17 (A) and
chromosomes 3, 4, and 7 (B).
Each “probe” is actually a set of
previously described PCR primers which flank a defined dinucleotide repeat (53–55). Formal
sizing of polymorphic fragments
was not performed, but the largest was arbitrarily assigned a 1,
the next largest, a 2, and so on.
Genomic DNA from a normal
control, the mother (ES), and
the patient (RS) was analyzed.
Data used in preparing this figure were derived from the
GDB(TM) Human Genome
Data Base at Johns Hopkins
University in Baltimore on December 14, 1994 at 11:00 a.m.
and May 10, 1995 at 3:30 p.m.
eastern time.
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end (position 20507) of exon 9 and at several positions in the
flanking introns (data not shown). Rather than characterize
the effect of each nucleotide change, we introduced the two
exon 9 sequence alterations of the mutant allele into the context of the maternal wild-type allele, and showed that the presence of both was required for abnormal splicing. Such cooperativity between widely spaced sequence variants suggested
that a perturbation of pre-mRNA secondary structure might
be central to the exon skipping phenotype. We used the computer program RNAFOLD to predict the most energy-efficient RNA secondary structure for the four possible combinations of sequence variants in exon 9 (data not shown). An
identical structure was predicted when either a C or an A was
present at position 20507 (the 59 polymorphism), indicating
that not all nucleotide changes alter structure as predicted by
the input parameters of our model. However, the mutant A at
position 20624 produced a dramatic alteration in the predicted
RNA secondary structure. Interestingly, with the A at position
20624, different structures were obtained for a C or an A at the
59 end of the exon, with the latter variant predicting a long intraexonic hairpin loop. We are unaware of any naturally occurring alternative exon splicing which results from cooperation
between widely spaced sequence variations at the 59 and 39 regions of a single exon and which do not involve the consensus
splice sequences. It is possible that the A variant at position
20624 alters the GPIIIa pre-mRNA conformation, but only in
combination with the A variant at position 20507 does the conformation preclude efficient splicing of exon 9, perhaps by interfering with exon scanning or by reducing the affinity of
small nuclear ribonuclear proteins for their cis-acting elements. We realize that such modeling may not accurately reflect the situation in vivo, but at least it is consistent with the
data shown in Fig. 5. Such effects of secondary exon structure
on splicing have been postulated by others (62, 63). Matsuo et
al. observed exon skipping despite normal consensus splice sequences when the exon contained a 52-bp deletion, and
showed a significant alteration in the predicted secondary
structure of the pre-mRNA (64). Carothers et al. found that
intraexonic sequence changes could counter the effects of allelic mutations within the splice site consensus (65). Such revertants restored normal splicing. Interestingly, the position of
these revertant mutations clustered between 5 and 8 bp upstream of the splice donor site.
We are also intrigued by the utilization of the cryptic splice
site (AGGT) 5 bp upstream of the exon 10 splice acceptor site
in all transcripts containing the exon 9 deletion. Scrutiny of the
intron upstream of GPIIIa exon 10 (Fig. 3) reveals that the
cryptic splice site has a preceding polypyrimidine tract that
better conforms to the mammalian consensus (61) than does
the constitutively utilized splice site. Of note, use of the normal
splice acceptor site violates the accepted rule in which the first
AG downstream of the branch point is utilized (66, 67). We
were unable to detect any transcripts from normal individuals
lacking exon 9 or which contained exon 9 and used the cryptic
splice site. We have previously presented data indicating that
maintenance of an ORF can act as an additional level of scrutiny during splice site selection, based upon the skipping of exons containing nonsense mutations (52) and the restoration of
the normal splicing phenotype by revertant mutations that restore the ORF (68). In the majority of these cases, simple skipping of the exon was sufficient to restore the ORF. In the mutant GPIIIa allele characterized in the current study, the
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majority of detectable GPIIIa transcripts have maintained an
ORF after exon 9 skipping by a more complex mechanism:
that of utilizing the cryptic splice acceptor 5 bp upstream of
exon 10. While far reaching consequences of secondary structure changes in exon 9 could be invoked to account for the simultaneous occurrence of exon skipping and cryptic splice site
utilization, in light of our prior work, it is tempting to speculate
that the selection of an alternative splice site acceptor for intron 10 is a consequence of the premature termination codon
that would result upon exon 9 skipping if the normal acceptor
were utilized.
Because the mutant GPIIIa transcript maintained an open
reading frame, it would be predicted to translate into protein.
GPIIIa stability (and plasma membrane insertion) requires assembly with GPIIb (69). However, no GPIIIa was detected by
Western blot analysis. Presumably, the loss of 45 and/or the
addition of two amino acids from exon 9 skipping or the 5-bp
insertion, respectively, results in a GPIIIa molecule unable to
pair with GPIIb. Exon 9 contains residues 350–395 of mature
GPIIIa, including an NH2-linked glycosylation site and 2 cysteine residues which are disulfide linked to one another (70);
the 5-bp insertion would produce a Val-Ser insertion. Although expression studies are beyond the scope of this work,
we speculate that residues GPIIIa 350–395 are important for
GPIIb-IIIa assembly and/or stability. This would be consistent
with data of Calvete et al. who analyzed proteolytic fragments
of the isolated receptor and identified GPIIIa residues 324–366
as one of three interfaces between GPIIb and GPIIIa (71).
Unfortunately, the patient’s father is not available for study
so we cannot definitively eliminate the possibility of consanguinity in this case. Nevertheless, there is strong evidence that
the patient has two identical copies of chromosome 17: (a)
there are two copies of the GPIIIa gene (Fig. 6); (b) based on
calculated and determined allelic frequencies, we estimate that
there is only a 1 in 5,000 chance that an individual would be
homozygous for the six polymorphisms we have studied. These
chances become extraordinarily small when considering the
patient is also homozygous for the G→A mutation. Many lines
of evidence suggest that the chromosome 17 disomy in this patient is uniparental and not the result of consanguinity. First,
repeated questioning of the patient’s mother consistently revealed no history of consanguinity. Second, the patient was homozygous at all six chromosome 17 markers, but at just one of
six markers on chromosomes 3, 4, and 7. There is no reason
why, in consanguinity, one chromosome would be selectively
affected. Third, crossovers during the first meiotic division
make it quite unlikely that related individuals would have
identical copies of chromosome 17. Even the two consanguinous unions most likely to cause the inheritance of two copies of the same chromosome 17 (father–daughter or brother–
sister) would require an extremely rare series of meioses in
which either double crossovers in the intervals of markers we
have assayed and/or nonrecombination took place. Taken together, and in the context of the biology of meiotic crossovers,
our haplotype studies are not compatible with consanguinity
and are most consistent with uniparental isodisomy.
We are unaware of other human diseases caused by disomy
of chromosome 17. While a patient with Silver-Russell syndrome due to a paternally inherited balanced translocation
[t(17;20)(q25;q13)] has been reported (72), this involved only a
portion of chromosome 17. We believe that our patient lacks a
paternal chromosome 17, raising issues regarding imprinted

genes on this chromosome. Genomic, or gametic, imprinting
refers to the phenomenon in which a gamete-specific modification in the parental generation can sometimes lead to functional differences between maternal and paternal genomes in
diploid cells of the offspring (73). Genes become altered in
some as yet undefined fashion during gametogenesis such that
they are either expressed or not expressed during embryogenesis and in adult life. For any given imprinted gene, it is predictable that only the allele inherited from a parent of a specific gender will be expressed. Human genetic disorders and
cancers have been described in which the phenotype results
from a mutation in only the expressed parental allele (74, 75).
Only a handful of imprinted genes have been described; none
are on human chromosome 17 (74). Assuming maternal isodisomy in patient RS, the fact that her phenotype is restricted to
Glanzmann thrombasthenia implies chromosome 17 must not
harbor genes expressed exclusively from the paternal allele
whose loss leads to significant disease. Likewise, chromosome
17 must not harbor genes expressed exclusively from the maternal allele that lead to significant disease when expressed
from two copies.
In summary, we have described a patient with Glanzmann
thrombasthenia and an abnormally spliced GPIIIa mRNA due
to the concerted effect of allelic sequence variants. Because
the nucleotide substitutions neither created premature termination codons nor altered known splice site sequences, our
data support the hypothesis that pre-mRNA secondary structure influences splicing. The choice of a cryptic splice site is
consistent with cellular mechanisms favoring transcripts containing an ORF. Finally, we have presented evidence that the
thrombasthenic phenotype in this patient may result from uniparental isodisomy for a maternal chromosome containing a
mutant GPIIIa gene, a finding which carries certain implications regarding imprinted genes on chromosome 17. Such observations highlight the potential secondary gain that can be
afforded by the comprehensive analysis of mutant alleles associated with human disease.

Acknowledgments
We wish to thank Dr. Andrew Feinberg for helpful discussions regarding genomic imprinting, Dr. Garry Cutting for normal AfricanAmerican DNA samples and assistance with the RNAFOLD program, and Ray Kendzior, Jr. for technical assistance.
Supported by grants HL-43020, HL-02815, HL-36260, and HL19278 from the National Institutes of Health, by the Rogers-Wilbur
Foundation, and by the Smilow Family Foundation. Dr. Bray is an
Established Investigator of the American Heart Association. Dr.
Dietz is a Richard Starr Ross Research Scholar. Dr. Bell is the
Edythe Harris Lucas-Clara Lucas Lynn Professor of Hematology.

References
1. George, J.N., J.P. Caen, and A.T. Nurden. 1990. Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood. 75:1383–1395.
2. George, J.N., and A.T. Nurden. 1994. Inherited disorders of the platelet
membrane: Glanzmann thrombasthenia, Bernard-Soulier syndrome and other
disorders. In Hemostasis and Thrombosis. Basic Principles and Clinical Practice. R.W. Coleman, J. Hirsh, V.J. Marder, and E.W. Salzman, editors. J.B. Lippincott Co., Philadelphia. 652–672.
3. Glanzmann, E. 1918. Hereditare hamorrhagische thrombasthenie: ein
beitrag zur pathologie der blut plattchen. J. Kinderkr. 88:1–13.
4. Nurden, A.T., and J.P. Caen. 1974. An abnormal platelet glycoprotein
pattern in three cases of Glanzmann’s thrombasthenia. Br. J. Haematol. 28:253–
260.

5. Marguerie, G.A., E.F. Plow, and T.S. Edgington. 1979. Human platelets
possess an inducible and saturable receptor specific for fibrinogen. J. Biol.
Chem. 254:5357–5363.
6. Bennett, J.S., and G. Vilaire. 1979. Exposure of platelet fibrinogen receptors by ADP and Epinephrine. J. Clin. Invest. 64:1393–1401.
7. McEver, R.P., N.L. Baenziger, and P.W. Majerus. 1980. Isolation and
quantitation of the platelet membrane glycoprotein deficient in thrombasthenia
using a monoclonal hybridoma antibody. J. Clin. Invest. 66:1311–1318.
8. Nachman, R.L., L.K. Lawrence, and L. Leung. 1982. Complex formation
of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J. Clin. Invest.
69:263–269.
9. Gogstad, G.O., F. Brosstad, M.-B. Krutnes, I. Hagen, and N.O. Solum.
1982. Fibrinogen-binding properties of the human platelet glycoprotein IIb-IIIa
complex: a study using crossed-radioimmunoelectrophoresis. Blood. 60:663–
671.
10. Bennett, J.S., G. Vilaire, and D.B. Cines. 1982. Identification of the fibrinogen receptor on human platelets by photoaffinity labeling. J. Biol. Chem.
257:8049–8054.
11. Coller, B.S., E.I. Peerschke, L.E. Scudder, and C.A. Sullivan. 1983. A
murine monoclonal antibody that completely blocks the binding of fibrinogen
to platelets produces a thrombasthenic-like state in normal platelets and binds
to glycoproteins IIb and/or IIIa. J. Clin. Invest. 72:325–338.
12. Bennett, J.S., J.A. Hoxie, S.F. Leitman, G. Vilaire, and D. Cines. 1983.
Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal
antibody. Proc. Natl. Acad. Sci. USA. 80:2417–2421.
13. Poncz, M., R. Eisman, R. Heidenreich, S.M. Silver, G. Vilaire, S. Surrey,
E. Schwartz, and J.S. Bennett. 1987. Structure of the platelet membrane glycoprotein IIb. J. Biol. Chem. 262:8476–8482.
14. Bray, P.F., J.-P. Rosa, G.I. Johnston, D.T. Shiu, R.G. Cook, C. Lau,
Y.W. Kan, R.P. McEver, and M.A. Shuman. 1987. Platelet glycoprotein IIb:
chromosomal location and tissue expression. J. Clin. Invest. 80:1812–1817.
15. Fitzgerald, L.A., B. Steiner, S.C. Rall, Jr., S.-S. Lo, and D.R. Phillips.
1987. Protein sequence of endothelial glycoprotein IIIa derived from a cDNA
clone. J. Biol. Chem. 262:3936–3949.
16. Rosa, J.-P., P.F. Bray, O. Gayet, G.I. Johnston, R.G. Cook, K.W. Jackson, M.A. Shuman, and R.P. McEver. 1988. Cloning of glycoprotein IIIa cDNA
from human erythroleukemia cells and localization of the gene to chromosome
17. Blood. 72:593–600.
17. Heidenreich, R., R. Eisman, S. Surrey, K. Delgrosso, J.S. Bennett, E.
Schwartz, and M. Poncz. 1990. Organization of the gene for platelet glycoprotein IIb. Biochemistry. 29:1232–1244.
18. Zimrin, A.B., S. Gidwitz, A. Lord, E. Schwartz, J.S. Bennett, G.C.
White III, and M. Poncz. 1990. The genomic organization of platelet glycoprotein IIIa. J. Biol. Chem. 265:8590–8595.
19. Villa-Garcia, M., L. Li, G. Riely, and P.F. Bray. 1994. Isolation and
characterization of a TATA-less promoter for the human b3 integrin gene.
Blood. 83:668–676.
20. Bray, P.F., and M.A. Shuman. 1990. Identification of an abnormal gene
for the GPIIIa subunit of the platelet fibrinogen receptor resulting in Glanzmann thrombasthenia. Blood. 75:881–888.
21. Bray, P.F. 1994. Inherited disease of platelet glycoproteins: considerations for rapid molecular characterization. Thromb. Haemostasis. 72:492–502.
22. Plow, E.F., and M.H. Ginsberg. 1989. Cellular adhesion: GPIIb-IIIa as a
prototypic adhesion receptor. Prog. Hemostasis Thromb. 9:117–156.
23. Hynes, R.O. 1992. Integrins: modulation, and signaling in cell adhesion.
Cell. 69:11–25.
24. Loftus, J.C., T.E. O’Toole, E.F. Plow, A. Glass, A.L. Frelinger, and
M.H. Ginsberg. 1990. A b3 integrin mutation abolishes ligand binding and alters
divalent cation-dependent conformation. Science (Wash. DC). 249:915–918.
25. Bajt, M.L., M.H. Ginsberg, A.L. Frelinger III, M.C. Berndt, and J.C.
Loftus. 1992. A spontaneous mutation of integrin aIIbb3 (platelet glycoprotein
IIb-IIIa) helps define a ligand binding site. J. Biol. Chem. 267:3789–3794.
26. Lanza, F., A. Stierl, D. Fournier, M. Morales, G. André, A.T. Nurden,
and J.-P. Cazenave. 1992. A new variant of Glanzmann’s thrombasthenia
(Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein III 214Arg→214Trp mutation. J. Clin. Invest. 89:1995–
2004.
27. Chen, Y.-P., I. Djaffar, I. Pidard, B. Steiner, A.-M. Cieutat, J.P. Caen,
and J.-P. Rosa. 1992. Ser752→Pro mutation in the cytoplasmic domain of integrin b3 subunit and defective activation of platelet integrin aIIbb3 (glycoprotein
IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proc. Natl. Acad. Sci.
USA. 89:10169–10173.
28. Djaffar, I., and J.-P. Rosa. 1993. A second case of variant Glanzmann’s
thrombasthenia due to substitution of platelet GPIIIa (integrin b3) Arg214 by
Trp. Hum. Mol. Genet. 2:2179–2180.
29. Chen, Y.-P., T.E. O’Toole, J. Ylanne, J.-P. Rosa, and M.H. Ginsberg.
1994. A point mutation in the integrin b3 cytoplasmic domain (S752 → P) impairs
bidirectional signaling through aIIbb3 (platelet glycoprotein IIb-IIIa). Blood. 84:
1857–1865.
30. Kato, A., K. Yamamoto, S. Miyazaki, S.M. Jung, M. Mori, and N. Aoki.
1992. Molecular basis for Glanzmann’s thrombasthenia (GT) in a compound
heterozygote with the GPIIb gene: a proposal for the classification of GT based

Thrombasthenia Due to Novel Exon Skipping and Chromosome 17 Isodisomy

1753

on the biosynthetic pathway of glycoprotein IIb-IIIa complex. Blood. 79:3212–
3218.
31. Jin, Y., H. Dietz, A.T. Nurden, and P.F. Bray. 1993. SSCP is a rapid and
effective method for the identification of mutations and polymorphisms in the
gene for GPIIIa. Blood. 82:2281–2288.
32. Simsek, S., H. Heyboer, L.G. de Bruihne, R. Goldschmeding, H.T.M.
Cuijpers, and A.E.G., von dem Borne. 1993. Glanzmann’s thrombasthenia
caused by homozygosity for a splice defect that leads to deletion of the first coding exon of the glycoprotein IIIa mRNA. Blood. 81:2044–2049.
33. Iwamoto, S., E. Nishiumi, E. Kajii, and S. Ikemoto. 1994. An exon 28
mutation resulting in alternative splicing of the glycoprotein IIb transcript and
Glanzmann’s thrombasthenia. Blood. 83:1017–1023.
34. Poncz, M., S. Rifat, B.S. Coller, P.J. Newman, S.J. Shattil, T. Parrella, P.
Fortina, and J.S. Bennett. 1994. Glanzmann thrombasthenia secondary to a
Gly273→Asp mutation adjacent to the first calcium-binding domain of platelet
glycoprotein IIb. J. Clin. Invest. 93:172–179.
35. Wilcox, D.A., J.L. Wautier, D. Pidard, and P.J. Newman. 1994. A single
amino acid substitution flanking the fourth calcium binding domain of aIIb prevents maturation of the aIIbb3 integrin complex. J. Biol. Chem. 269:4450–4457.
36. Chen, F., B.S. Coller, and D.L. French. 1993. Homozygous mutation of
platelet glycoprotein IIIa (b3) Cys374→Tyr in a Chinese patient with Glanzmann
thrombasthenia. Blood. 82:163a (Abstr.).
37. Wilcox, D.A., C.M. Paddock, J. Gill, and P.J. Newman. 1995. Glanzmann thrombasthenia resulting from a single amino acid substitution between
the second and third calcium-binding domains of GPIIb. Role of the GPIIb
amino terminus in integrin subunit association. J. Clin. Invest. 95:1553–1560.
38. Schlegel, N., O. Gayet, M.C. Morel-Kopp, B. Wyler, M.F. HurtaudRoux, C. Kaplan, and J. McGregor. 1995. The molecular genetic basis of Glanzmann’s thrombasthenia in a gypsy population in France: identification of a new
mutation on the aIIb gene. Blood. 86:977–982.
39. Tomiyama, Y., H. Kashiwagi, S. Kosugi, M. Shiraga, Y. Kanayama, Y.
Kurata, and Y. Matsuzawa. 1995. Abnormal processing of the glycoprotein IIb
transcript due to a nonsense mutation in exon 17 associated with Glanzmann’s
thrombasthenia. Thromb. Haemostasis. 73:756–762.
40. Peretz, H., N. Rosenberg, S. Usher, E. Graff, P.J. Newman, B.S. Coller,
and U. Seligsohn. 1995. Glanzmann’s thrombasthenia associated with deletioninsertion and alternative splicing in the glycoprotein IIb gene. Blood. 85:414–
420.
41. Sharp, P.A. 1987. Splicing of messenger RNA precursors. Science
(Wash. DC). 235:766–771.
42. Wu, J.Y., and T. Maniatis. 1993. Specific interactions between proteins
implicated in splice site selection and regulated alternative splicing. Cell. 75:
1061–1070.
43. Talerico, M., and S.M. Berget. 1990. Effect of 59 splice site mutations on
splicing of the preceding intron. Mol. Cell. Biol. 10:6299–6305.
44. Chen, I.-T, and L.A. Chasin. 1993. Direct selection for mutations affecting specific splice sites in a hamster dihydrofolate reductase minigene. Mol.
Cell. Biol. 13:289–300.
45. Nakai, K., and H. Sakamoto. 1994. Construction of a novel database
containing aberrant splicing mutations of mammalian genes. Gene. 141:171–
177.
46. Jin, Y., H.C. Dietz, and P.F. Bray. 1993. A mutation in the GPIIIa gene
results in an mRNA splicing abnormality and suggests maintenance of reading
frame is a deliberate process. Blood. 82:210a (Abstr.).
47. Faraday, N., P. Goldschmidt-Clermont, K. Dise, and P.F. Bray. 1994.
Quantitation of soluble fibrinogen binding to platelets by fluorescence activated flow cytometry. J. Lab. Clin. 123:728–740.
48. Coller, B.S., D.A. Cheresh, E. Asch, and E. Seligsohn. 1991. Platelet vitronectin receptor expression differentiates Iraqi–Jewish from Arab patients
with Glanzmann thrombasthenia in Israel. Blood. 77:75–83.
49. Djaffar, I., D. Vilette, P.F. Bray, and J.-P. Rosa. 1991. Quantitative isolation of RNA from human platelets. Thromb. Res. 62:127–135.
50. Bray, P.F., G. Barsh, J.P. Rosa, X.Y. Luo, E. Magenis, and M.A. Shuman. 1988. Physical linkage of the genes for platelet membrane glycoprotein IIb
and IIIa. Proc. Natl. Acad. Sci. USA. 85:8683–8687.
51. Eldadah, Z.A., T. Brenn, H. Furthmayr, and H.C. Dietz. 1995. Expression of a mutant human fibrillin allele upon a normal human or murine genetic
background recapitulates a Marfan cellular phenotype. J. Clin. Invest. 95:874–
880.
52. Dietz, H.C., and R.J. Kendizior, Jr. 1994. Maintenance of an open reading frame as an additional level of scrutiny during splice site selection. Nature

1754

Jin et al.

Genet. 8:183–188.
53. Weber, J.L., A.E. Kwitek, P.E. May, M.R. Wallace, F.S. Collins, and
D.H. Ledbetter. 1990. Dinucleotide repeat polymorphisms at the D17S250 and
D17S261 loci. Nucleic Acids Res. 18:4640a (Abstr.).
54. Weissenbach, J., G. Gyapay, C. Dib, A. Vignal, J. Morissette, P. Millasseau, G. Vaysseix, and M. Lathrop. 1992. A second-generation linkage map of
the human genome. Nature (Lond.). 359:794–801.
55. Gyapay, G., J. Morissette, A. Vignal, C. Dib, C. Fizames, P. Millasseau,
S. Marc, G. Bernardi, M. Lathrop, and J. Weissenbach. 1994. The 1993-94
Généthon human genetic linkage map. Nature Genet. 7:246–339.
56. Fasman, K.H., A.J. Cuticchia, and D.T. Kinsbury. 1994. The GDB(TM)
human genome data base anno 1994. Nucleic Acids Res. 22:3462–3469.
57. Cuticchia, A.J., K.H. Fasman, D.T. Kinsbury, R.J. Robbins, and P.L.
Pearson. 1993. The GDB(TM) human genome data base anno 1993. Nucleic
Acids Res. 21:3003–3006.
58. Zucker, M., and P. Stiegler. 1981. Optimal computer folding of large
RNA sequences using thermodynamics and auxiliary information. Nucleic Acids Res. 9:133–148.
59. Lapalme, G., R.J. Cedergren, and D. Sankoff. 1982. An algorithm for
the display of nucleic acid secondary structure. Nucleic Acids Res. 10:8351–
8356.
60. Mitchell, G.A., J.E. Looney, L.C. Brody, G. Steel, M. Suchanek, J.F.
Engelhardt, H.F. Willard, and D. Valle. 1988. Human ornithine-d-aminotransferase. cDNA cloning and analysis of the structural gene. J. Biol. Chem. 263:
14288–14295.
61. Padgett, R.A., P.J. Grabowski, M.M. Konarska, S. Seiler, and P.A.
Sharp. 1986. Splicing of messenger RNA precursors. Annu. Rev. Biochem. 55:
1119–1150.
62. Steingrimsdottir, H., G. Rowley, G. Dorado, J. Cole, and A.R. Lehmann. 1992. Mutations which alter splicing in the human hypoxanthine guanine
phosphoribosyltransferase gene. Nucleic Acids Res. 20:1201–1208.
63. Menichini, P., A. Inga, G. Fronza, R. Iannone, P. Degan, P. Campomenosi, and A. Abbondandolo. 1994. Defective splicing induced by 4NQO in
the hamster hprt gene. Mutat. Res. 323:159–165.
64. Matsuo, M., H. Nishio, Y. Kitoh, U. Francke, and H. Nakamura. 1992.
Partial deletion of a dystrophin gene leads to exon skipping and to loss of an intra-exon hairpin structure from the predicted mRNA precursor. Biochem. Biophys. Res. Commun. 182:495–500.
65. Carothers, A.M., G. Urlaub, D. Grunberger, and L.A. Chasin. 1993.
Splicing mutants and their second-site suppressors at the dihydrofolate reductase locus in Chinese hamster ovary cells. Mol. Cell. Biol. 13:5085–5098.
66. Smith, C.W., E.B. Porro, J.G. Patton, and B. Nadal-Ginard. 1989. Scanning from an independently specified branch point defines the 39 splice site of
mammalian introns. Nature (Lond.). 342:243–247.
67. Smith, C.W., T.T. Chu, and B. Nadal-Ginard. 1993. Scanning and competition between AGs are involved in 39 splice site selection in mammalian introns. Mol. Cell. Biol. 13:4939–4952.
68. Dietz, H.C., D. Valle, C.A. Francomano, R.J. Kendzior, R.E. Pyeritz,
and G.R. Cutting. 1993. The skipping of constitutive exons in vivo induced by
nonsense mutations. Science (Wash. DC). 259:680–683.
69. O’Toole, T.E., J.C. Loftus, E.F. Plow, A.A. Glass, J.R. Harper, and
M.H. Ginsberg. 1989. Efficient surface expression of platelet GPIIb-IIIa requires both subunits. Blood. 74:14–18.
70. Calvete, J.J., A. Henschen, and J. González-Rodríguez. 1991. Assignment of disulphide bonds in human platelet GPIIIa. A disulphide pattern of the
b-subunits of the integrin family. Biochem. J. 274:63–71.
71. Calvete, J.J., K. Mann, M.V. Alvarez, M.M. López, and J. GonzálezRodríguez. 1992. Proteolytic dissection of the isolated platelet fibrinogen receptor, integrin GPIIb/IIIa: localization of GPIIb and GPIIIa sequences putatively
involved in the subunit interface and in intrasubunit and intrachain contacts.
Biochem. J. 282:523–532.
72. Ramirez-Duenas, M.L., C. Medina, R. Ocampo-Campos, and H. Rivera.
1992. Severe Silver-Russell syndrome and translocation. Clin. Genet. 41:51–53.
73. Barlow, D.P. Imprinting: a gamete’s point of view. 1994. Trends Genet.
10:194–199.
74. Nicholls, R.D. 1994. New insights reveal complex mechanisms involved
in genomic imprinting. Am. J. Hum. Genet. 54:733–740.
75. Rainier, S., L.A. Johnson, C.J. Dobry, A.J. Ping, P.E. Grundy, and A.P.
Feinberg. 1993. Relaxation of imprinted genes in human cancer. Nature
(Lond.). 362:747-749.

